Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

mentById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >LGND). It is being developed by GlaxoSmithKline. Eltrombopag is an investigational compound that has not received regulatory approval in any market for any indication at this time.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Note to Editors

PROMACTA(R) is a registered trademark of GlaxoSmithKline group of companies and is the proposed trade name in the United States.

To access the latest GSK news, visit http://us.gsk.com/

Inquiries:

US Media inquiries: Jeff McLaughlin 1 919 483 2839

Mary Anne Rhyne 1 919 483 2839

Nancy Pekarek 1 215 751 7709

US Analyst/Investor inquiries: Frank Murdolo 1 215 751 7002

Tom Curry 1 215 751 5419

References:

(1) US Food and Drug Administration. The Orphan Drug act (as amended). Accessed May 2008.
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Time Physical Activity on Mobility Limitation in Old Age ... risk of mobility limitation in old age, whereas leisure-time ... a study which followed up 5,200 public sector employees ... Gerontology Research Center in Finland and the Finnish Institute ... repetitive, wears the body and lasts for several hours ...
(Date:4/23/2014)... Methylphenidate, also known as Ritalin, may prevent the depletion ... Science , a journal of the Association for Psychological ... a diet or trying to focus attention on a ... suggests one potential explanation for this difficulty: Exerting self-control ... to exert self-control effectively on subsequent tasks. , "It ...
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... Society of ... Surgeons Annual Meeting, BALTIMORE, Oct. 28 One facelift or ... In fact,plastic surgeons analyze facial features and configurations to,individualize results based ... at the American Society of Plastic Surgeons (ASPS) Plastic,Surgery 2007 conference ...
... Annual Meeting, BALTIMORE, Oct. 28 While the ... to for fear of sagging,breasts. However, breastfeeding alone has ... first-of-its-kind study presented today at the,American Society of Plastic ... women who come in for breast surgery tell us ...
... in which the bladder forms outside of the abdomen ... with the same condition, according to a small study ... The condition, known as bladder exstrophy, requires a series ... early adolescence.The findings are being reported at the American ...
... 2007 MedImmune, Inc. today announced it will present ... 2007 National Conference & Exhibition, adding to the companys ... syncytial virus (RSV), a leading cause of hospitalization among ... that provide key insights into how we can optimize ...
... connected, study finds , THURSDAY, Oct. 25 (HealthDay ... a follow-up osteoporosis management program that includes electronic ... , Osteoporosis -- which increases the risk of ... 65 and older. Medication can greatly reduce fracture ...
... American Red Cross,Blood Services national system continues to ship ... to help stabilize the blood,supply in the region affected ... provided nearly 2,000 blood products to date,in support of ... drives in southern California have been curtailed due to ...
Cached Medicine News:Health News:Facelift, Botox, or Both? Depends Upon Your Decade of Life 2Health News:Facelift, Botox, or Both? Depends Upon Your Decade of Life 3Health News:Breastfeeding Does Not Create Sagging Breasts; Study Throws Out Old Wives' Tale 2Health News:MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics 2Health News:Older Women Gain From Good Post-Fracture Care 2Health News:American Red Cross Blood Services Supports Blood Needs of Southern California 2
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical ... CMED ), a leading China-based ... its unaudited financial results for the ... 2011 ("1Q FY2011") today.1 Q ...
... More than a decade of targeted Muscular Dystrophy Association-funded ... support of the MDA Labor Day Telethon and thousands ... providing financial assistance for the start of the first ... pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, ...
Cached Medicine Technology:China Medical Technologies Reports First Fiscal Quarter Financial Results 2China Medical Technologies Reports First Fiscal Quarter Financial Results 3China Medical Technologies Reports First Fiscal Quarter Financial Results 4China Medical Technologies Reports First Fiscal Quarter Financial Results 5China Medical Technologies Reports First Fiscal Quarter Financial Results 6China Medical Technologies Reports First Fiscal Quarter Financial Results 7China Medical Technologies Reports First Fiscal Quarter Financial Results 8China Medical Technologies Reports First Fiscal Quarter Financial Results 9China Medical Technologies Reports First Fiscal Quarter Financial Results 10China Medical Technologies Reports First Fiscal Quarter Financial Results 11China Medical Technologies Reports First Fiscal Quarter Financial Results 12China Medical Technologies Reports First Fiscal Quarter Financial Results 13China Medical Technologies Reports First Fiscal Quarter Financial Results 14China Medical Technologies Reports First Fiscal Quarter Financial Results 15China Medical Technologies Reports First Fiscal Quarter Financial Results 16China Medical Technologies Reports First Fiscal Quarter Financial Results 17China Medical Technologies Reports First Fiscal Quarter Financial Results 18China Medical Technologies Reports First Fiscal Quarter Financial Results 19MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 2MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 3MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 4
...
... System is your system. CONMED's family of ... specialty. New, state-of-the art generators feature proprietary ... a continuous synchronization of current and voltage ... architecture enables the system to sample current ...
... biologically based adhesive supplied as a ... of a liquid substrate and crosslinker ... bleeding. When combined the ... a prepared wound and tenaciously adhere ...
... DERMABOND* Topical Skin Adhesive gives you ... adhesive is intended for topical application only ... of wounds from surgical incisions, including punctures ... cleansed, trauma-induced lacerations. DERMABOND adhesive may be ...
Medicine Products: